Medline $MDLN Holdings Boosted by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. grew its stake in Medline (NASDAQ:MDLN) by 14.1% in the 3rd quarter, Holdings Channel.com reports. The fund owned 1,856,810 shares of the company’s stock after purchasing an additional 229,817 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in Medline were worth $64,431,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Janus Henderson Group PLC boosted its position in Medline by 8.4% during the first quarter. Janus Henderson Group PLC now owns 11,451,861 shares of the company’s stock valued at $506,546,000 after purchasing an additional 887,240 shares during the last quarter. Banque Pictet & Cie SA grew its stake in Medline by 2.0% in the third quarter. Banque Pictet & Cie SA now owns 7,455,089 shares of the company’s stock valued at $258,692,000 after purchasing an additional 142,939 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund grew its stake in Medline by 233.3% in the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 5,000,000 shares of the company’s stock valued at $222,500,000 after purchasing an additional 3,500,000 shares in the last quarter. Bessemer Group Inc. grew its stake in Medline by 39,404.0% in the first quarter. Bessemer Group Inc. now owns 3,504,006 shares of the company’s stock valued at $155,929,000 after purchasing an additional 3,495,136 shares in the last quarter. Finally, Unisphere Establishment increased its position in shares of Medline by 50.5% during the 1st quarter. Unisphere Establishment now owns 2,482,500 shares of the company’s stock worth $110,471,000 after purchasing an additional 832,500 shares during the last quarter.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on MDLN shares. BMO Capital Markets reiterated an “outperform” rating and set a $47.00 price objective on shares of Medline in a research note on Thursday, August 6th. BTIG Research reissued a “buy” rating and issued a $55.00 price objective on shares of Medline in a report on Thursday, August 27th. Stifel Nicolaus decreased their target price on shares of Medline from $50.00 to $45.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. William Blair restated an “outperform” rating on shares of Medline in a report on Wednesday, September 23rd. Finally, TD Cowen dropped their price target on shares of Medline from $53.00 to $45.00 and set a “buy” rating on the stock in a research report on Monday, August 10th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $46.69.

Medline Trading Down 1.2%

MDLN opened at $34.88 on Friday. Medline has a 1-year low of $31.49 and a 1-year high of $50.88. The stock’s fifty day simple moving average is $34.73 and its 200 day simple moving average is $37.92. The company has a debt-to-equity ratio of 0.66, a quick ratio of 2.61 and a current ratio of 4.33.

Medline (NASDAQ:MDLN) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.32 by $0.18. The business had revenue of $7.68 billion for the quarter. Equities research analysts expect that Medline will post 1.51 EPS for the current fiscal year.

Insider Buying and Selling at Medline

In other news, major shareholder Private Ltd Gic sold 2,570,999 shares of the firm’s stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $35.35, for a total transaction of $90,884,814.65. Following the completion of the sale, the insider owned 20,231,483 shares in the company, valued at approximately $715,182,924.05. This trade represents a 11.28% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders have sold 10,787,572 shares of company stock valued at $382,784,591 over the last 90 days. 0.81% of the stock is owned by corporate insiders.

Medline Company Profile

Medline Industries, Inc is a medical-supply manufacturer and distributor headquartered in Northfield, Illinois. The company provides products and supply-chain services to healthcare organizations, including hospitals, ambulatory surgery centers, physician offices, long-term care facilities, home health providers and other care settings.

Its product portfolio includes medical-surgical supplies, surgical and operating-room products, patient-care items, examination gloves, protective apparel, laboratory products, respiratory-care equipment, durable medical equipment and products for infection prevention.